Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Dementia risk higher in herpes zoster ophthalmicus patients

24 Nov 2017
The government will focus on building "community networks" to support those with dementia instead.

The risk of subsequent dementia is significantly higher in patients with herpes zoster ophthalmicus (HZO), a recent study from Taiwan has shown.

After retrieving the records from the Taiwan Longitudinal Health Insurance Database 2005, researchers followed 846 HZO patients (mean age 62.2±12.5 years) for 5 years and assessed the development of dementia. Cox proportional hazards analysis was performed to determine the risk of dementia in HZO patients compared to 2,538 non-HZO controls (mean age 61.4±13.3 years) in the comparison group.

Over the 5-year follow-up, the incidence rate of dementia in the entire study population was 5.24 per 1,000 person-years. Respective incidence rates for the HZO and control groups were 10.15 and 3.61 per 1,000 person-years, yielding in significantly different dementia-free accumulated survival rates between the groups (p<0.001).

After adjusting for covariates like age, sex and comorbidities, those with HZO were found to be at a significantly higher risk of dementia than controls (hazard ratio [HR], 2.97; 95 percent CI, 1.90 to 4.67).

To account for potential surveillance bias, the research team excluded four patients who were diagnosed with dementia within 2 months of their index date. Subsequent analysis showed the same elevated dementia risk for HZO patients (crude HR, 2.82; 1.80 to 4.41).

Subgroup analysis showed that the trend was independent of sex, as both male (HR, 3.41; 1.78 to 6.53) and female (HR, 2.98; 1.54 to 5.77) HZO patients had higher risk of dementia compared to controls.

Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.